Cargando…
Acute and subchronic toxicity of the antitumor agent rhodium (II) citrate in Balb/c mice after intraperitoneal administration
This study aimed to investigate potential acute and subchronic toxicity of rhodium (II) citrate in female Balb/c mice after intraperitoneal injections. In the acute test, independent groups received five doses; the highest dose (107.5 mg/kg) was equivalent to 33 times that used in our previous repor...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5598461/ https://www.ncbi.nlm.nih.gov/pubmed/28962450 http://dx.doi.org/10.1016/j.toxrep.2015.07.010 |
_version_ | 1783263910686621696 |
---|---|
author | Carneiro, Marcella L.B. Lopes, Cláudio A.P. Miranda-Vilela, Ana L. Joanitti, Graziella A. da Silva, Izabel C.R. Mortari, Márcia R. de Souza, Aparecido R. Báo, Sônia N. |
author_facet | Carneiro, Marcella L.B. Lopes, Cláudio A.P. Miranda-Vilela, Ana L. Joanitti, Graziella A. da Silva, Izabel C.R. Mortari, Márcia R. de Souza, Aparecido R. Báo, Sônia N. |
author_sort | Carneiro, Marcella L.B. |
collection | PubMed |
description | This study aimed to investigate potential acute and subchronic toxicity of rhodium (II) citrate in female Balb/c mice after intraperitoneal injections. In the acute test, independent groups received five doses; the highest dose (107.5 mg/kg) was equivalent to 33 times that used in our previous reports. The other doses were chosen as proportions of the highest, being 80.7 (75%), 53.8 (50%), 26.9 (25%) or 13.8 mg/kg (12.5%). Animals were monitored over 38 days and no severe signs of toxicity were observed, according to mortality, monitoring of adverse symptoms, hematological, biochemical and genotoxic parameters. We conclude that the median lethal dose (LD(50)) could be greater than 107.5 mg/kg. In the subchronic test, five doses of Rh(2)Cit (80, 60, 40, 20 or 10 mg/kg) were evaluated and injections were conducted on alternate days, totaling five applications per animal. Paclitaxel (57.5 mg/kg) and saline solution were controls. Clinical observations, histopathology of liver, lung and kidneys and effects on hematological, biochemistry and genotoxic records indicated that Rh(2)Cit induced no severe toxic effects, even at an accumulated dose up to 400 mg/kg.We suggest Rh(2)Cit has great potential as an antitumor drug without presenting acute and subchronic toxicity. |
format | Online Article Text |
id | pubmed-5598461 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-55984612017-09-28 Acute and subchronic toxicity of the antitumor agent rhodium (II) citrate in Balb/c mice after intraperitoneal administration Carneiro, Marcella L.B. Lopes, Cláudio A.P. Miranda-Vilela, Ana L. Joanitti, Graziella A. da Silva, Izabel C.R. Mortari, Márcia R. de Souza, Aparecido R. Báo, Sônia N. Toxicol Rep Article This study aimed to investigate potential acute and subchronic toxicity of rhodium (II) citrate in female Balb/c mice after intraperitoneal injections. In the acute test, independent groups received five doses; the highest dose (107.5 mg/kg) was equivalent to 33 times that used in our previous reports. The other doses were chosen as proportions of the highest, being 80.7 (75%), 53.8 (50%), 26.9 (25%) or 13.8 mg/kg (12.5%). Animals were monitored over 38 days and no severe signs of toxicity were observed, according to mortality, monitoring of adverse symptoms, hematological, biochemical and genotoxic parameters. We conclude that the median lethal dose (LD(50)) could be greater than 107.5 mg/kg. In the subchronic test, five doses of Rh(2)Cit (80, 60, 40, 20 or 10 mg/kg) were evaluated and injections were conducted on alternate days, totaling five applications per animal. Paclitaxel (57.5 mg/kg) and saline solution were controls. Clinical observations, histopathology of liver, lung and kidneys and effects on hematological, biochemistry and genotoxic records indicated that Rh(2)Cit induced no severe toxic effects, even at an accumulated dose up to 400 mg/kg.We suggest Rh(2)Cit has great potential as an antitumor drug without presenting acute and subchronic toxicity. Elsevier 2015-07-17 /pmc/articles/PMC5598461/ /pubmed/28962450 http://dx.doi.org/10.1016/j.toxrep.2015.07.010 Text en © 2015 Published by Elsevier Ireland Ltd. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Article Carneiro, Marcella L.B. Lopes, Cláudio A.P. Miranda-Vilela, Ana L. Joanitti, Graziella A. da Silva, Izabel C.R. Mortari, Márcia R. de Souza, Aparecido R. Báo, Sônia N. Acute and subchronic toxicity of the antitumor agent rhodium (II) citrate in Balb/c mice after intraperitoneal administration |
title | Acute and subchronic toxicity of the antitumor agent rhodium (II) citrate in Balb/c mice after intraperitoneal administration |
title_full | Acute and subchronic toxicity of the antitumor agent rhodium (II) citrate in Balb/c mice after intraperitoneal administration |
title_fullStr | Acute and subchronic toxicity of the antitumor agent rhodium (II) citrate in Balb/c mice after intraperitoneal administration |
title_full_unstemmed | Acute and subchronic toxicity of the antitumor agent rhodium (II) citrate in Balb/c mice after intraperitoneal administration |
title_short | Acute and subchronic toxicity of the antitumor agent rhodium (II) citrate in Balb/c mice after intraperitoneal administration |
title_sort | acute and subchronic toxicity of the antitumor agent rhodium (ii) citrate in balb/c mice after intraperitoneal administration |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5598461/ https://www.ncbi.nlm.nih.gov/pubmed/28962450 http://dx.doi.org/10.1016/j.toxrep.2015.07.010 |
work_keys_str_mv | AT carneiromarcellalb acuteandsubchronictoxicityoftheantitumoragentrhodiumiicitrateinbalbcmiceafterintraperitonealadministration AT lopesclaudioap acuteandsubchronictoxicityoftheantitumoragentrhodiumiicitrateinbalbcmiceafterintraperitonealadministration AT mirandavilelaanal acuteandsubchronictoxicityoftheantitumoragentrhodiumiicitrateinbalbcmiceafterintraperitonealadministration AT joanittigraziellaa acuteandsubchronictoxicityoftheantitumoragentrhodiumiicitrateinbalbcmiceafterintraperitonealadministration AT dasilvaizabelcr acuteandsubchronictoxicityoftheantitumoragentrhodiumiicitrateinbalbcmiceafterintraperitonealadministration AT mortarimarciar acuteandsubchronictoxicityoftheantitumoragentrhodiumiicitrateinbalbcmiceafterintraperitonealadministration AT desouzaaparecidor acuteandsubchronictoxicityoftheantitumoragentrhodiumiicitrateinbalbcmiceafterintraperitonealadministration AT baosonian acuteandsubchronictoxicityoftheantitumoragentrhodiumiicitrateinbalbcmiceafterintraperitonealadministration |